Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma

Non Small Cell Lung Cancer Clinical Trial

— METABO-ICI  

Official title:

: Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04189679
• Other study ID #: 38RC19.133
• Secondary ID: 2019-A01255-52
• Status: Completed
• Start date: January 3, 2020
• Est. completion date: January 27, 2023

Study information

• Verified date: January 2024
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Immune checkpoints inhibitors (ICI) are becoming new standards of care for Non-Small Cell Lung Carcinoma (NSCLC) treatment. To date, no powerful predictive biomarker of response has been found. The investigators hypothesize that metabolomics profile could represent a potent biomarker of response to ICI

Description:

Immune checkpoints inhibitors (ICI) are becoming new standards of care for Non-Small Cell Lung Carcinoma (NSCLC) treatment, both as first and second line of treatment. To date, no powerful predictive biomarker of response has been found. It has been recently shown that microbiota composition could dictate the ability of patients to respond to ICI. Since, the microbiota produces circulating metabolites that will subsequently act on immune system, the investigators hypothesized that metabolic signature, reflecting microbiota function, could represent a predictive biomarker of response to ICI. Primary objective is to identify baseline metabolic signature (metabolomics analysis by Mass spectrometry) associated to ICI response. Secondary objectives are to link metabolic signature with microbiota composition (metagenomics analysis RNA 16S) and immune profile, and altogether with clinic response to ICI. Profile evolution (metabolic, metagenomics and immune) will be also analyzed at 2-month post ICI initiation and at tumor progression, if any. In order to do so, the investigators thus plan to enroll 60 NSCLC patients treated by ICI as 1st, 2nd or 3rd line of treatment in CHUGA in 18 months. Blood as well feces will be collected prior to, and at 2 month following ICI treatment initiation as well as at progression. Will be excluded from this study, patients that have received antibiotic or corticotherapy 2 or 4 weeks before ICI initiation, respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: January 27, 2023
• Est. primary completion date: January 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• NSCLC diagnosis
• Patient treated by a ICI in first, second or third line of treatment, or by the combination of chemotherapy and IPCI in first line of treatment
• Patient with at least one measurable lesion as defined by RECIST

Exclusion Criteria:

• Patient treated with antibiotic treatment within 2 weeks before the start of ICI or corticosteroids (>20 mg per day) within 4 weeks before the start of ICI

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Other:
• Immune signature in serum associated to the metabolic signature
Immune signature in serum associated to the metabolic signature

Genetic:
• Meta-genomic signature of intestinal flora
Meta-genomic signature of intestinal flora

Locations

Country	Name	City	State
France	University Hospital, Grenoble	La Tronche	Isère

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of the change from baseline Metabolic signature as predictive factor of the ICI response at 6 months or at the tumoral progression	To identify the link of the change from baseline of Metabolic signature in serum (metabolomics analysis performed using a Mass spectrometry) and the ICI response at 6 months or at the tumoral progression	baseline, 6 months or tumoral progression
Secondary	Identification of the link between the Meta-genomic and immune signatures and the metabolic signature at 6 months or at the tumoral progression	To identify the link between the Meta-genomic signature of intestinal flora (microbiota composition analysed by RNA 16 S) with the Immune signature in serum and the metabolic signature at 6 months or at the tumoral progression	6 months or tumoral progression
Secondary	Identification of the link between the Meta-genomic and immune signatures and ICI response at 6 months or at the tumoral progression	To identify the link between the Meta-genomic signature of intestinal flora with the Immune signature in serum and the ICI response at 6 months or at the tumoral progression	6 months or tumoral progression
Secondary	Description of the profile change of Meta-genomic signature	To describe the change from baseline of the Meta-genomic signature at 2 months or at the tumoral progression	2 months or tumoral progression
Secondary	Description of the profile change of Immune signature at 2 months or at the tumoral progression	To describe the change from baseline of the Immune signature at 2 months or at the tumoral progression	Baseline and 2 months or tumoral progression
Secondary	Identification of the link between the profile change of meta-genomic signature and the ICI response at 2 months or at the tumoral progression	To identify the link between the profile change from baseline of meta-genomic signature and the ICI response at 2 months or at the tumoral progression	Baseline and (2 months or tumoral progression)
Secondary	Identification of change of immune signature and the ICI response at 2 months or at the tumoral progression	To identify the link between the profile change from baseline of immune signature and the ICI response at 2 months or at the tumoral progression	Baseline and (2 months or tumoral progression)
Secondary	Description of overall survival under ICI at 6 months or at the tumoral progression	To describe of the overall survival under ICI at 6 months or at the tumoral progression	6 months or tumoral progression
Secondary	Description of the survival without progression under ICI at 6 months or at the tumoral progression	To describe the survival without progression under ICI at 6 months or at the tumoral progression	6 months or tumoral progression